MPT: FDA Reiterates Warning on Absorb Stent

ACC Conference Reporter

TCT 2017 | DENVER — As new 3- and 4-year data emerged from the ABSORB clinical trials, the FDA updated its cautions to healthcare professionals about continuing risk seen with the first-generation Absorb bioresorbable vascular scaffold (BVS) stent. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics, TCT17

< Back to Listings